Floatz logo

VITPSO

Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer Action NetworkSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

32 Active assets in the Metastatic Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Olaparib
Lantern Pharma Inc.
Phase 3BB
Epirubicin
Minia University
Phase 3BB
Pembrolizumab
Mayo Clinic
Phase 2BB
Irinotecan
National Cancer Institute (NCI)
Phase 3BB
Irinotecan Sucrosofate
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

VITPSO is also rated in:

primary cutaneous T-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
67 / 100
View asset →
Metastatic Pancreatic CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →